At the time of writing, Castle Biosciences Inc [CSTL] stock is trading at $19.36, down -1.48%. An important factor to consider is whether the stock is rising or falling in short-term value. The CSTL shares have gain 32.15% over the last week, with a monthly amount drifted -2.42%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Castle Biosciences Inc [NASDAQ: CSTL] stock has seen the most recent analyst activity on December 14, 2023, when Guggenheim initiated its Buy rating and assigned the stock a price target of $25. Previously, Scotiabank started tracking the stock with Sector Outperform rating on January 05, 2023, and set its price target to $54. On January 07, 2022, Stephens initiated with a Overweight rating and assigned a price target of $59 on the stock. Lake Street started tracking the stock assigning a Buy rating and suggested a price target of $94 on April 30, 2021. KeyBanc Capital Markets initiated its recommendation with a Overweight and recommended $70 as its price target on November 10, 2020. Canaccord Genuity reiterated a Buy rating for this stock on December 27, 2019, and upped its price target to $35. In a note dated August 19, 2019, SVB Leerink initiated an Outperform rating and provided a target price of $28 on this stock.
For the past year, the stock price of Castle Biosciences Inc fluctuated between $14.59 and $35.84. Currently, Wall Street analysts expect the stock to reach $33.5 within the next 12 months. Castle Biosciences Inc [NASDAQ: CSTL] shares were valued at $19.36 at the most recent close of the market. An investor can expect a potential return of 73.04% based on the average CSTL price forecast.
Analyzing the CSTL fundamentals
According to Castle Biosciences Inc [NASDAQ:CSTL], the company’s sales were 346.27M for trailing twelve months, which represents an -0.94% plunge. Gross Profit Margin for this corporation currently stands at 0.8% with Operating Profit Margin at -0.07%, Pretax Profit Margin comes in at -0.03%, and Net Profit Margin reading is -0.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.02 and Total Capital is -0.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Castle Biosciences Inc [NASDAQ:CSTL] has a current ratio of 6.85. On the other hand, the Quick Ratio is 6.69, and the Cash Ratio is 1.62. Considering the valuation of this stock, the price to sales ratio is 1.62, the price to book ratio is 1.23.
Transactions by insiders
Recent insider trading involved MAETZOLD DEREK J, Pres. & Chief Exec. Officer, that happened on Jun 27 ’25 when 17632.0 shares were sold. Pres. & Chief Exec. Officer, MAETZOLD DEREK J completed a deal on Jun 27 ’25 to sell 4944.0 shares. Meanwhile, Officer Derek Maetzold bought 16932.0 shares on Jun 27 ’25.
